A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous RPX2014 and RPX7009 Alone and in Combination in Healthy Adult Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous RPX2014 and RPX7009 Alone and in Combination in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2015

At a glance

  • Drugs Meropenem/vaborbactam (Primary) ; Meropenem; Vaborbactam
  • Indications Bacterial infections
  • Focus Adverse reactions
  • Sponsors Rempex Pharmaceuticals
  • Most Recent Events

    • 04 Dec 2013 Status changed from recruiting to completed, according to a Medicines Company media release.
    • 08 Aug 2013 Planned End Date changed from 1 Aug 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 08 Aug 2013 Planned number of patients changed from 30 to 86 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top